INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS

Clinical trials for INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS explained in plain language.

Never miss a new study

Get alerted when new INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS trials appear

Sign up with your email to follow new studies for INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental drug tazemetostat offered to patients with rare, aggressive tumors

Disease control NO_LONGER_AVAILABLE

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

Matched conditions: INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS

Sponsor: Epizyme, Inc. • Aim: Disease control

Last updated Jul 03, 2026 19:22 UTC

INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS

Get alerted when new INTRAMEDULLARY SPINAL CORD SCHWANNOMATOSIS trials appear

Experimental drug tazemetostat offered to patients with rare, aggressive tumors